Twenty years after the first, exclusively white human genomes were fully sequenced, science finds itself in the same position as the rest of society: with the uncomfortable realization that old inequalities are often morphing, rather than disappearing. Vocal racists – scientists of the stripe of a James Watson – are by no means a thing of the past. But they are only the tip of the iceberg.
BioWorld looks at translational medicine, including: Neurons forget who they are in Alzheimer’s disease; Sensor can predict hallucinogenic serotonin receptor effects.
Keeping you up to date on recent developments in oncology, including: New test lends insight into aggressiveness of prostate cancer, could reduce biopsy; Loss of cell polarity is lung cancer precursor; A different path to specificity for Ras inhibitors; Thin films for detection, calibration of proton beams.
Twenty years after the first, exclusively white human genomes were fully sequenced, science finds itself in the same position as the rest of society: with the uncomfortable realization that old inequalities are often morphing, rather than disappearing.
Keeping you up to date on recent developments in neurology, including: Fast brainwave oscillations identify, localize epileptic brain; Sleep biomarkers linked to neurodegenerative disease; Autophagy chaperone targets aggregation-prone proteins.
The enzyme proprotein convertase subtilisin/kexin type 9 (PCSK9) plays a major role in the regulation of blood LDL cholesterol levels. Now, new research shows that targeting PCSK9 may also potentiate checkpoint blockade.
Senti Biosciences Inc. stands to receive more than $645 million in up-front, opt-in and milestone payments through a new collaboration and option agreement with Spark Therapeutics Inc.
Cachexia, Teresa Zimmers told the audience at the Annual Meeting of the American Association for Cancer Research (AACR), is "woefully understudied for the outsized impact it has on cancer patients." The condition, which is currently defined as weight loss and muscle wasting, is the direct cause of death in an estimated 25% to 30% of cancer patients. But it is the main subject of only 0.1% of research papers and 0.2% of clinical trials.
